nAMD: New Drugs and Practice Patterns to Improve Patient Outcomes

This program may include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction

Limitations of Current Approaches

Unmet Needs of Anti-VEGF Therapy

Current Anti-VEGF Therapy for nAMD: Limitations

Desired Attributes of New Treatments

Seven-Year Outcomes in Ranibizumab-Treated Patients: A Multicenter Cohort Study (SEVEN-UP)

Observational Study of FRB Database Eyes: Adherence to Treatment May Improve Results

Complete Polyp Regression: EVEREST and PLANET Studies at Month 12

New Treatments in Development

Molecular Sizes of Anti-VEGF Agents

Brolucizumab Phase 3 Studies in nAMD: HAWK and HARRIER Studies

HAWK and HARRIER Studies: Brolucizumab Reduced Dosing Frequency

HAWK/HARRIER: Primary and Sensitivity Analyses

Brolucizumab Met The Primary Endpoint of Non-Inferiority in Change in BCVA From Baseline to Week 48

HAWK and HARRIER Studies: Anatomical Results at Week 16

Significantly Fewer Patients on Brolucizumab Had IRF and/or SRF at Week 16 and Week 48

Polypoidal Choroidal Vasculopathy

Designed Ankyrin Repeat Protein (DARPin®): Abicipar Pegol

Abicipar Pegol: REACH Phase 2 Clinical Study Visual Acuity Results

RG7716 Phase 1 Safety/Tolerability and Efficacy Summary Treatment Refractory Patients With Average Disease Duration of 2.9 Years

Phase 2 Studies Using RG7716

Desired Attributes of New Treatments

EVEREST II Change in BCVA of the Study Eye: Treatment Comparison at Months 12 and 24

EVEREST II Complete Polyp Regression: Treatment Comparison at Months 12 and 24

Conclusions

Abbreviations

Abbreviations (cont)